Press Releases

Oct 01, 2012
GW Appoints Chris Tovey as Chief Operating Officer London, UK; October 1st 2012: GW Pharmaceuticals plc (AIM: GWP) today announces the appointment, effective today, of Christopher John Tovey to the newly created position of Chief Operating Officer. Chris, aged 47, joins GW having gained a wealth of
Jun 22, 2012
German G-BA establishes positive additional benefit of Sativex® in Multiple Sclerosis Spasticity German G-BA establishes positive additional benefit of Sativex® in Multiple Sclerosis Spasticity German G-BA establishes positive additional benefit of Sativex® in Multiple Sclerosis Spasticity German
May 22, 2012
Third phase III Sativex® cancer pain trial commences GW’s cancer pain clinical programme is being wholly funded by Otsuka Pharmaceutical Co. Ltd, which has licensed the US commercialisation rights to this product. The trials are designed to obtain approval in this indication from the Food & Drug
May 22, 2012
Porton Down, UK, 22 May 2012: GW Pharmaceuticals plc (AIM: GWP, “GW” or “the Group”), the specialty pharmaceutical company focused on cannabinoid science, announces its interim results for the six months ended 31 March 2012. COMMERCIAL: STRONG PROGRESS Sativex ® in-market sales grow to £5.4m (H1
Apr 23, 2012
London, UK; Tokyo, Japan; April 23 2012: GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd. today announce the publication in the Journal of Pain(1), the official journal of the American Pain Society, of the full results from a Phase IIb dose-ranging trial evaluating the efficacy
Apr 16, 2012
Porton Down, UK; 16 April 2012: GW Pharmaceuticals plc (AIM: GWP) confirms that it has now earned the €11.9 million milestone payment due as a result of the recently amended terms of its licence agreement with Almirall S.A. (announced on 15 March 2012).